Glenmede Trust’s abrdn Life Sciences Investors HQL Stock Holding History

Glenmede Trust’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-19	Closed	–	–	2706
2016 Q4	$0	Hold	19	–	–	﹤0.01%	2532
2016 Q3	$0	Hold	19	–	–	﹤0.01%	2627
2016 Q2	$0	Hold	19	–	–	﹤0.01%	2609
2016 Q1	$0	Sell	19 -10,800	-100%	-$196K	﹤0.01%	2663
2015 Q4	$255K	Buy	10,819 +8,781	+431%	+$218K	﹤0.01%	1108
2015 Q3	$45K	Buy	+2,038	New	+$57.1K	﹤0.01%	1619

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Glenmede Trust's HQL Position: Q1 2017 in Review

Glenmede Trust sold out of abrdn Life Sciences Investors (HQL) in Q1 2017, closing a stake of 19 shares.

Glenmede Trust first reported a position in HQL in Q3 2015 and held it in 6 quarters. The position peaked at $255K in Q4 2015. 41 funds tracked by Wall St. Rank hold HQL as of Q1 2017.

Glenmede Trust reported no remaining abrdn Life Sciences Investors position as of Q1 2017 after selling out during the quarter.
Glenmede Trust sold 19 abrdn Life Sciences Investors shares in Q1 2017.
Glenmede Trust first reported a position in abrdn Life Sciences Investors in Q3 2015 and held it in 6 quarters.
Glenmede Trust's abrdn Life Sciences Investors position peaked at $255K in Q4 2015.
41 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2017.

Based on Glenmede Trust's 13F filing for Q1 2017, filed 15 May 2017.